Mortality in Patients with Biopsy-proven Giant Cell Arteritis: A South Australian Population-based Study

JEM NINAN, ANH-MINH NGUYEN, ANTONIA COLE, MAUREEN RISCHMUELLER, THOMAS DODD, PETER ROBERTS-THOMSON, and CATHERINE L. HILL

ABSTRACT. Objective. To compare mortality rates and cause of death in patients with biopsy-proven giant cell arteritis (GCA) with those in the general population.

Methods. Patients with biopsy-proven GCA were identified from pathology reports of temporal artery biopsies in South Australia, from January 1, 1992, to December 31, 2006. All patients with biopsy-proven GCA were linked to the South Australian Births, Death and Marriage Registry to identify deaths until December 31, 2006. Standardized mortality ratios and relative survival (ratio of observed survival in GCA group to expected survival of general South Australian population, matched by age, sex, and calendar time) were calculated. The cause of death recorded on the death certificate was also documented.

Results. There were 225 cases of biopsy-proven GCA (163 women and 62 men). The mean age at diagnosis of GCA was 78.2 years. The mean followup period was 66.2 months (SD 47.1 mo). During the followup period, there were 71 deaths in the GCA group (50 women, 21 men). The standardized mortality ratio was 0.99 (95% CI 0.77–1.25). The relative survival for different followup periods demonstrates that patients with GCA experienced similar mortality to the general population (age-matched and sex-matched). Death from cardiovascular causes (45%) was the most common, followed by infection (17%) and cancer (17%). Infection was a significantly more common cause of death in the first year (chi-squared, p = 0.0002).

Conclusion. Our population-based cohort study did not demonstrate any increased mortality risk for patients diagnosed with biopsy-proven GCA. The risk of death from infection early in the disease may be increased. (First Release Aug 15 2011; J Rheumatol 2011;38:2215–17; doi:10.3899/jrheum.101254)

Key Indexing Terms:
MORTALITY RATE                      GIANT CELL ARTERITIS                       BIOPSY-PROVEN

Giant cell arteritis (GCA) is a disease of the elderly that is associated with increased morbidity both from complications of vasculitis such as blindness, stroke, myocardial infarction, and aortic aneurysm and from complications of corticosteroid therapy including infection, osteoporosis, and impaired glycemic control. Previous studies of mortality associated with GCA have shown conflicting results, with some studies suggesting no effect on mortality1,2,3 and others that suggest increased mortality4,5. Many of these studies have been limited by small sample size or inclusion of GCA cases not confirmed by biopsy. The aim of this study was to determine the mortality rate of patients with biopsy-proven GCA compared to the general population and to determine causes of death among these patients.

MATERIALS AND METHODS

Ascertainment of biopsy-proven GCA cases. All pathology reports of patients who underwent temporal artery biopsy were identified from pathology laboratories at the 3 major South Australian adult teaching hospitals (The Queen Elizabeth Hospital, the Royal Adelaide Hospital, and Flinders Medical Centre). These laboratories process about 85% of biopsy specimens from both public and private hospitals in South Australia. Temporal artery biopsies were identified at The Queen Elizabeth Hospital and the Royal Adelaide Hospital in the period January 1, 1992, to December 31, 2006, and at Flinders Medical Centre from January 1, 1995, to December 31, 2006. All pathology reports of temporal artery biopsies during this period were reviewed and patients with biopsy-proven GCA were identified. Patients were defined as having biopsy-proven GCA if this diagnosis was made by the reviewing pathologist on the diagnostic report6.

Ascertainment of death. Using Automatch software (MatchWare Technologies Inc., Tampa, FL, USA), all patients identified with biopsy-proven GCA were linked to the South Australian Registry of Births, Deaths and Marriages (BDM) to identify all deaths among these subjects prior to January 1, 2007. The BDM registry records all deaths that occur in South Australia (SA) and gathers data about all deaths in Australia. For those patients who died in SA, the primary cause of death as documented by the
The Journal of Rheumatology 2011; 38:10; doi:10.3899/jrheum.101254

The strengths of our study are that it included only patients with biopsy-proven GCA to an age-matched and sex-matched control population. Our study showed similar mortality rates in patients with GCA compared to the general population, thus, by definition this group will have a SMR of 1.0.

RESULTS

There were 225 cases of biopsy-proven GCA; of these, 163 (72.4%) were women and 62 (27.6%) were men. The majority of patients were white (224/225, 99.5%). The mean age at diagnosis of GCA was 78.2 years. The mean followup period was 66.2 months (SD 47.1 mo). During the followup period, there were 71 deaths in the GCA group (50 women, 21 men). The median time to death post-diagnosis was 49 months. The overall SMR was 0.99 (95% CI 0.77–1.25). The SMR for women was 1.12 (95% CI 0.83–1.48) and for men, 0.86 (95% CI 0.53–1.32). The relative survival for different followup periods demonstrates that patients with GCA experienced similar mortality to the general population (age-matched and sex-matched; Table 1, Figure 1). Observed survival is described in Table 2. Death from cardiovascular causes (45%) was the most common, followed by infection (17%) and cancer (17%; Table 3). Cardiovascular causes included myocardial infarction (11), cerebrovascular events (6), and mesenteric infarction (4). GCA was recorded on only 12 death certificates (17%). The most frequent cause of death in the first year from GCA diagnosis was infection-related (8/15, 53%), including pneumonia (4) and pseudomonas septicemia (2). Infection was a significantly more common cause of death in the first year (chi-squared 14.03, p = 0.0002) than in later years, when cardiovascular causes were more common. There were no deaths due to cerebrovascular accident in the first year after diagnosis.

DISCUSSION

Studies that have demonstrated increased mortality of patients with GCA compared to the general population have generally been the studies with fewer patients (Bisgard9, n = 34; Garcia-Porrua4, n = 54; Nesher10, n = 43; Uddhammar11, n = 136). Studies that showed no increased mortality tended to involve more patients (Gonzalez-Gay2, n = 109; Gran3, n = 42; Matteson12, n = 205; Salvarani13, n = 173; Nordborg and Bengtsson7, n = 284).

The earliest study comparing GCA mortality to the general population was performed in Olmsted County, Minnesota, USA14, in 1978 and revealed no increased risk. A subsequent study of the GCA cohort based at the Mayo Clinic also revealed no increased risk13. The only multinational study, by Matteson, et al12, included 205 patients with GCA from the United States, Canada, and Mexico, and also demonstrated no with a confirmed diagnosis of GCA through biopsy and a large sample size (only a Swedish study by Nordborg and Bengtsson in 1989 with 284 patients being larger7). Another strength of our study is that death was ascertained from the state death registry and not from case note records alone, a practice that can lead to incomplete death ascertainment. Our study represents the first study of mortality in GCA outside Europe or North America. Previous studies have been from the United Kingdom, Europe, and the United States. We demonstrated no difference in survival from the general population at any time, a finding that contrasts with several studies that demonstrated increased mortality at 5 years, but no effect at 10–11 years4,8.

Figure 1. Survival rate of patients with giant cell arteritis compared with age-matched general population.

Table 1. Relative survival (± SE) of patients with biopsy-proven giant cell arteritis (GCA) in South Australia, compared to the general population, 1992–2006 (n = 225). All data are percentages.

<table>
<thead>
<tr>
<th>Year from Biopsy</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>GCA</td>
<td>99.3±3.1</td>
<td>99.8±4.4</td>
<td>98.7±5.8</td>
<td>100.5±6.8</td>
<td>100.4±8.1</td>
<td>98.7±9.6</td>
<td>100.5±10.8</td>
<td>100.3±12.4</td>
<td>103.8±13.8</td>
<td>104.2±15.8</td>
</tr>
</tbody>
</table>

The earliest study comparing GCA mortality to the general population was performed in Olmsted County, Minnesota, USA14, in 1978 and revealed no increased risk. A subsequent study of the GCA cohort based at the Mayo Clinic also revealed no increased risk13. The only multinational study, by Matteson, et al12, included 205 patients with GCA from the United States, Canada, and Mexico, and also demonstrated no
increased risk (SMR 1.03). However, studies from Denmark, Spain, Israel, and Utah, USA, have shown variably increased risks (SMR 1.8–2.4)⁴,⁸,⁹,¹⁰. These conflicting results are likely related to differences in ascertainment of GCA, as well as variability of duration and completeness of followup.

Infection was identified as a common cause of death in the first 2 years after GCA diagnosis, and this may well be related to immunosuppression from higher doses of corticosteroids at that stage. This has implications with respect to infection prevention strategies in these patients, including vaccination and early treatment of infections.

We observed no cases of reactivated tuberculosis and there is no reported information about deaths or infection from tuberculosis in patients with GCA from high tuberculosis prevalence areas such as Eastern Europe or Asia.

Of additional interest was the 4 deaths observed from mesenteric infarction, which occurred 2–4 years after GCA diagnosis. Unfortunately, we do not have clinical information concerning corticosteroid use at time of death. A case series from Massachusetts recognized this complication in 12 patients with mesenteric ischemia and GCA; it was fatal in 50%¹⁵.

We found that 6 patients had cerebrovascular accident listed as cause of death, of whom 3 had associated cardiac failure or atrial fibrillation, but there was no mention of stroke related to large artery occlusion on any of the death certificates. Although aortic aneurysm has been traditionally described as a complication in GCA, we did not find ruptured aneurysm mentioned as a cause of death on any of the death certificates in our group of patients.

One of the limitations of our study is that we do not have clinical information on the patients including information about GCA treatment, disease course, or other comorbidities such as preexisting cardiovascular disease and lung disease.

Our study demonstrated that patients with GCA have similar mortality rates to the general population. However, the risk of death from infection early in the disease may be increased, suggesting that vigilance for infection in this period is required.

REFERENCES